Jing Zhang

US Patent:

20070087364, Apr 19, 2007

Filed:

Sep 27, 2006

Appl. No.:

11/527999

Inventors:

Joe Shuga - Cambridge RI, US
Linda Griffith - Cambridge MA, US
Harvey Lodish - Brookline MA, US
Leona Samson - Newton MA, US
Dharini Shah - Cambridge MA, US
Jing Zhang - Newton MA, US

Assignee:

Massachusetts Institute of Technology - Cambridge MA

International Classification:

C12Q 1/68

US Classification:

435006000

Abstract:

The present invention is directed to novel assays to measure the genotoxic effects of compounds on erythroid cells in vitro.

US Patent:

20130310384, Nov 21, 2013

Filed:

Oct 4, 2011

Appl. No.:

13/877419

Inventors:

Corinne E. Augelli-Szafran - Newton MA, US
Dai Lu - Boston MA, US
Hanxun Wei - West Roxbury MA, US
Jing Zhang - Lexington MA, US
Michael S. Wolfe - Newton MA, US
Dennis J. Selkoe - Jamaica Plain MA, US

Assignee:

THE BRIGHAM AND WOMEN'S HOSPITAL, INC. - Boston MA

International Classification:

C07C 311/16
C07C 311/18
C07D 295/32
C07D 263/14
C07D 213/42
C07C 311/19
C07D 271/06

US Classification:

5142388, 564 92, 514604, 548131, 514364, 548238, 514374, 546338, 514357, 544159

Abstract:

This invention relates generally to the discovery of sulfonamide-containing compounds that are inhibitors of γ-secretase.

US Patent:

20200165251, May 28, 2020

Filed:

May 8, 2018

Appl. No.:

16/611065

Inventors:

- Waltham MA, US
Thomas Francois Durand-Reville - Belmont MA, US
Satenig Guler - Waltham MA, US
Jan Romero - Arlington MA, US
Mark Sylvester - Waltham MA, US
Ruben Tommasi - Stow MA, US
Camilo Velez-Vega - Waltham MA, US
Xiaoyun Wu - Westborough MA, US
Jing Zhang - Sudbury MA, US

International Classification:

C07D 471/18
A61P 31/04

Abstract:

Provided herein are antibacterial compounds represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X, Y, R, R, and Rare as defined herein. Also provided are pharmaceutical compositions comprising the compounds of Formula I.

US Patent:

20190321185, Oct 24, 2019

Filed:

Mar 20, 2019

Appl. No.:

16/359178

Inventors:

- Cambridge MA, US
Kai Xu - Somerville MA, US
Jing Zhang - Somerville MA, US

International Classification:

A61F 2/36

Abstract:

A method of manufacturing a femoral stem for a hip implant includes forming a femoral neck extending from a proximal end of the femoral stem towards a distal end of the femoral stem, forming an upper section connected to and extending from the femoral neck towards the distal end of the femoral stem, and forming a lower section connected to and extending from the upper section to the distal end of the femoral stem. Further, a method for designing a femoral stem for a hip implant includes generating a customized femoral stem model to match an information of a patient, generating at least one proximal-distal solid rib in the upper section, calculating density and stress distributions for an open lattice and for a closed lattice, and selecting a unit cell type and a pore size for the open lattice and the closed lattice to match a density and/or a stiffness of the patient's femur.

US Patent:

20190202832, Jul 4, 2019

Filed:

Sep 15, 2017

Appl. No.:

16/333900

Inventors:

- Altrincham, Cheshire, GB
Janelle Comita-Prevoir - Northborough MA, US
Thomas Francois Durand-Reville - Belmont MA, US
Lise Gauthier - Waltham MA, US
Bill Moss - Prestbury, Cheshire, GB
John O'Donnell - Mattapoisett MA, US
Jan Romero - Arlington MA, US
Ruben Tommasi - Stow MA, US
Jeroen Cunera Verheijen - Westborough MA, US
Frank Wu - Shrewsbury MA, US
Xiaoyun Wu - Westborough MA, US
Jing Zhang - Sudbury MA, US

Assignee:

Entasis Therapeutics Limited - Altrincham, Cheshire

International Classification:

C07D 471/08
C07D 211/78
A61K 31/439
A61K 31/546
A61P 31/04

Abstract:

The present invention is directed to compounds which are beta-lactamase inhibitors. The compounds and their pharmaceutically acceptable salts are useful in combination with beta-lactam antibiotics, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of R, R, R, R, Rand Rare described herein.

US Patent:

20170216295, Aug 3, 2017

Filed:

Jul 27, 2015

Appl. No.:

15/501103

Inventors:

Blaise Lippa - Acton MA, US
Xin Zhang - Belmont MA, US
Jon Christian Baber - Somerville MA, US
Jan Antionette C. Romero - Somerville MA, US
Jing Zhang - Lexington MA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/519
C07D 487/04

Abstract:

Provided herein are compounds that inhibit CCR9 receptor function. Also provided herein are methods of treating inflammatory disease in a subject, comprising administering to the subject a compound of the invention. Accordingly, in one aspect, provided herein is a compound of Formula (1) or a pharmaceutically acceptable salt thereof. In another aspect, provided herein is a pharmaceutical composition, comprising a compound of Formula (1), and a pharmaceutically acceptable carrier.

US Patent:

20140243374, Aug 28, 2014

Filed:

Oct 4, 2012

Appl. No.:

14/349206

Inventors:

- Boston MA, US
Dai Lu - Boston MA, US
HanXun Wei - West Roxbury MA, US
Jing Zhang - Lexington MA, US
Michael S. Wolfe - West Newton MA, US
Dennis J. Selkoe - Jamaica Plain MA, US

International Classification:

C07C 311/20
C07D 213/71
C07C 311/19
C07D 309/14
C07D 309/06
C07D 405/12
C07D 207/09

US Classification:

514336, 514347, 514428, 514459, 514524, 514539, 514604, 5462821, 546293, 548567, 549424, 549426, 558413, 560 12, 564 92

Abstract:

This invention relates generally to the discovery of sulfonamide-containing compounds that are inhibitors of γ-secretase.